The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trastuzumab plus FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14).
 
Choong-kun Lee
No Relationships to Disclose
 
Hong Jae Chon
No Relationships to Disclose
 
Jaekyung Cheon
No Relationships to Disclose
 
Myung Ah Lee
No Relationships to Disclose
 
Hyeon-Su Im
No Relationships to Disclose
 
Joung-Soon Jang
No Relationships to Disclose
 
Min Hwan Kim
Research Funding - AstraZeneca; Daewoong Pharmaceutical
 
Chan-Young Ock
Employment - Lunit
Leadership - Lunit
Stock and Other Ownership Interests - Lunit; Medpacto; Y-Biologics
Consulting or Advisory Role - Idience; Medpacto; Y-Biologics
 
Jin Won Kim
No Relationships to Disclose
 
Hyung Soon Park
No Relationships to Disclose
 
Myoung Joo Kang
No Relationships to Disclose
 
Hye Jin Choi
No Relationships to Disclose